HCB301 is a first-in-class tri-specific immunotherapy targeting SIRPa-CD47, PD-1/PD-L1, and TGFB; it shows potent macrophage activation, T-cell restoration, and tumor microenvironment remodeling in preclinical solid tumor models. HanchorBio Inc. (TPEx: 7827), a global clinical-stage biotechnology company advancing next-generation immunotherapies for oncology and autoimmune diseases, today announced that the preclinical data on HCB301, a novel tri-specific […]

(Nasdaq:FRMI) In honor of those who served, Fermi, Inc., DBA Fermi America™, who is powering tomorrow's AI to ensure America wins the intelligence race, will release its financial results for the third quarter ended September 30, 2025, on Veterans Day, Tuesday, November 11, 2025. Fermi's management team will host a live webcast and conference call

— Reports third quarter results, including net income of $137 million, Adjusted EBITDA(1), excluding one-time transaction-related expenses(2), of $496 million and Distributable Cash Flow, as adjusted(1), of $326 million — Increases quarterly distribution by 1.25%; on track to meet distribution growth target of at least 5% for 2025 — Reports third quarter leverage of 3.9

Bedsure, a leading online home textile brand, is bringing peak luxury at fair prices with the launch of its new GentleSoft® Organic Cotton Sheet Set. Luxurious organic cotton sheets no longer mean spending $300. Bedsure is utilizing the finest premium fibers from Turkey's Aegean region – the same source behind some of the most luxurious

— Delivered double-digit growth in Specialty Nutrition Systems segment — Closed acquisition of Nexus Medical, providing a complementary technology for the Specialty Nutrition Systems segment — Raising and narrowing top-line guidance and adjusted EPS guidance for the full year Avanos Medical, Inc. (NYSE: AVNS) today reported third quarter 2025 financial results. https://mma.prnewswire.com/media/713850/Avanos_Logo.jpg “I am pleased

Interplay Learning, the leader in immersive learning for the skilled trades, today announced the expansion of its Apprenticeship Services and the launch of Engagement Services. These strategic services are designed to help organizations tackle two of the industry's biggest challenges: developing qualified workers and keeping learners engaged in ongoing training and professional development. https://mma.prnewswire.com/media/2812436/Interplay_Learning_Logo.jpg With

— Marketplace dealer volume growth of 14% YoY — Gross Merchandise Value (GMV) of approximately $7.3 billion, representing 9% YoY growth — Revenue of $498 million, representing 8% YoY growth, driven by 20% growth in auction fee revenue — Income from continuing operations of $48 million, representing 69% YoY growth — Adjusted EBITDA of $87

Secura Bio to Participate in the Jefferies Global Healthcare Conference in London GlobeNewswire November 05, 2025 BERKELEY HEIGHTS, N.J., Nov. 05, 2025 (GLOBE NEWSWIRE) — Secura Bio, Inc. (www.securabio.com), an integrated pharmaceutical company maximizing commercial outcomes for oncology medicines, today announced that Chip Romp, Chief Executive Officer, and Will Brown, Chief Financial Officer will participate

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) GlobeNewswire November 05, 2025 RESEARCH TRIANGLE PARK, N.C., Nov. 05, 2025 (GLOBE NEWSWIRE) — BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst's board of directors granted three newly-hired employees restricted stock units (RSUs) covering an aggregate of 30,700 shares of BioCryst

Astec Reports Third Quarter 2025 Results GlobeNewswire November 05, 2025 Third Quarter 2025 Overview (all comparisons are made to the corresponding prior year third quarter unless otherwise specified): Net sales of $350.1 million Net loss of $4.2 million; Adjusted net income of $10.8 million EBITDA of $13.8 million; Adjusted EBITDA of $27.1 million Diluted EPS